We are in the midst of a significant shift in pharmaceutical drug development, with many leading companies focusing increasingly on orphan drugs targeted at small niche markets.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year
